KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Halozyme Therapeutics (HALO) Other Gross PP&E Adjustments (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Other Gross PP&E Adjustments for 15 consecutive years, with $32.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Gross PP&E Adjustments rose 27.69% to $32.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $32.2 million, a 27.69% increase, with the full-year FY2025 number at $32.2 million, up 27.69% from a year prior.
  • Other Gross PP&E Adjustments was $32.2 million for Q4 2025 at Halozyme Therapeutics, down from $35.4 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $38.5 million in Q2 2022 to a low of -$18.4 million in Q1 2025.
  • A 5-year average of $19.9 million and a median of $17.0 million in 2021 define the central range for Other Gross PP&E Adjustments.
  • Peak YoY movement for Other Gross PP&E Adjustments: soared 149.29% in 2023, then tumbled 173.48% in 2025.
  • Halozyme Therapeutics' Other Gross PP&E Adjustments stood at $15.2 million in 2021, then crashed by 65.84% to $5.2 million in 2022, then skyrocketed by 149.29% to $12.9 million in 2023, then soared by 95.02% to $25.2 million in 2024, then grew by 27.69% to $32.2 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Other Gross PP&E Adjustments are $32.2 million (Q4 2025), $35.4 million (Q3 2025), and $32.9 million (Q2 2025).